CytoDyn (CYDY) Income from Continuing Operations (2010 - 2026)
CytoDyn's (CYDY) quarterly Income from Continuing Operations came in at 4690000.0 in Q1 2026, up 1.43% YoY from 4623916.29 in Q1 2025, and up 79.25% on a QoQ basis from 22607000.0 in Q4 2025.
CytoDyn (CYDY) Income from Continuing Operations (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Income from Continuing Operations data on file, last reported at 4690000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 1.43% year-over-year to 4690000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 38793000.0 (down 447.46% YoY) and the FY2025 annual result came in at 3745000.0, up 107.51% from the prior year.
- Income from Continuing Operations climbed to 4690000.0 in Q1 2026, from 22607000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19227000.0 in Q3 2024 to a low of 84121000.0 in Q2 2022.
- A 5-year average of 16714058.82 and a median of 11920000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 266.17% — and 2025, when it tumbled 374.14%.
- Tracing CYDY's Income from Continuing Operations over 5 years: stood at 26495000.0 in 2022, then soared by 63.91% to 9563000.0 in 2023, then soared by 50.14% to 4768000.0 in 2024, then sank by 374.14% to 22607000.0 in 2025, then jumped by 79.25% to 4690000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4690000.0 (Q1 2026), 22607000.0 (Q4 2025), and 5540000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | -4.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -4.69 Mn |
| Nov 30, 2025 | -22.61 Mn |
| Aug 31, 2025 | -5.54 Mn |
| May 31, 2025 | -5.96 Mn |
| Feb 28, 2025 | -4.76 Mn |
| Nov 30, 2024 | -4.77 Mn |
| Aug 31, 2024 | 19.23 Mn |
| May 31, 2024 | -16.79 Mn |
| Feb 29, 2024 | -11.92 Mn |
| Nov 30, 2023 | -9.56 Mn |
| Aug 31, 2023 | -11.57 Mn |
| May 31, 2023 | -18.61 Mn |
| Feb 28, 2023 | -13.70 Mn |
| Nov 30, 2022 | -26.50 Mn |
| Aug 31, 2022 | -20.99 Mn |
| May 31, 2022 | -84.12 Mn |
| Feb 28, 2022 | -41.29 Mn |
| Nov 30, 2021 | -40.08 Mn |
| Aug 31, 2021 | -45.34 Mn |
| May 31, 2021 | -70.07 Mn |